These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 35537059

  • 1. Unresectable Clival Giant Cell Tumor, Tumor Control With Denosumab After Relapse: A Case Report and Systematic Review of the Literature.
    Pionelli MG, Asaftei SD, Tirtei E, Campello A, Di Rosa G, Fagioli F.
    J Pediatr Hematol Oncol; 2022 Jul 01; 44(5):201-209. PubMed ID: 35537059
    [Abstract] [Full Text] [Related]

  • 2. Preoperative Cytoreduction of Clival Giant Cell Tumor: An Effective Replication of the Systemic Modality in the Skull Base.
    Sekar A, Rudrappa S, Gopal S, Ghosal N, Gupta V, Ts L.
    World Neurosurg; 2018 Nov 01; 119():97-102. PubMed ID: 30075260
    [Abstract] [Full Text] [Related]

  • 3. Role of Denosumab in Endoscopic Endonasal Treatment for Juvenile Clival Giant Cell Tumor: A Case Report and Review of the Literature.
    Inoue A, Ohnishi T, Kohno S, Nishikawa M, Nishida N, Ohue S.
    World Neurosurg; 2016 Jul 01; 91():674.e1-6. PubMed ID: 27113403
    [Abstract] [Full Text] [Related]

  • 4. Denosumab salvage therapy in an 11-year-old boy with locally recurrent unresectable giant cell tumor of the lumbar spine after surgery.
    Luo Y, Xiu P, Chen H, Zeng J, Song Y, Li T.
    Neurochirurgie; 2023 May 01; 69(3):101427. PubMed ID: 36828057
    [Abstract] [Full Text] [Related]

  • 5. Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review.
    Bardakhchyan S, Kager L, Danielyan S, Avagyan A, Karamyan N, Vardevanyan H, Mkhitaryan S, Papyan R, Zohrabyan D, Safaryan L, Sargsyan L, Harutyunyan L, Hakobyan L, Iskanyan S, Tamamyan G.
    Ital J Pediatr; 2017 Mar 29; 43(1):32. PubMed ID: 28356124
    [Abstract] [Full Text] [Related]

  • 6. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E.
    Lancet Oncol; 2019 Dec 29; 20(12):1719-1729. PubMed ID: 31704134
    [Abstract] [Full Text] [Related]

  • 7. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
    Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, Deshpande V.
    Am J Surg Pathol; 2016 Jan 29; 40(1):72-80. PubMed ID: 26414220
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Denosumab Treatment for a Residual Giant Cell Tumor of the Clivus: A Case Report and Review of the Literature.
    Huh A, Villelli N, Martinez D, Ting J, Birhiray R, Payner TD, Kulwin CG.
    World Neurosurg; 2018 Oct 29; 118():98-101. PubMed ID: 30010069
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Current management of giant-cell tumor of bone in the denosumab era.
    Nagano A, Urakawa H, Tanaka K, Ozaki T.
    Jpn J Clin Oncol; 2022 May 05; 52(5):411-416. PubMed ID: 35199172
    [Abstract] [Full Text] [Related]

  • 13. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
    Tsukamoto S, Tanaka Y, Mavrogenis AF, Kido A, Kawaguchi M, Errani C.
    Clin Orthop Relat Res; 2020 May 05; 478(5):1076-1085. PubMed ID: 31794487
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec 05; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.
    Rekhi B, Verma V, Gulia A, Jambhekar NA, Desai S, Juvekar SL, Bajpai J, Puri A.
    Pathol Oncol Res; 2017 Jan 05; 23(1):157-164. PubMed ID: 27722984
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A case of pelvic giant cell tumor of bone, complete remission with denosumab: long duration of response.
    Bilgetekin I, Mammadkhanli O, Basal FB, Kandemir O, Canbay S, Oksuzoglu B.
    Anticancer Drugs; 2020 Jun 05; 31(5):533-535. PubMed ID: 31743134
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T.
    BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567
    [Abstract] [Full Text] [Related]

  • 20. Metastatic giant cell tumour of bone: a narrative review of management options and approaches.
    Xu R, Choong PFM.
    ANZ J Surg; 2022 Apr 22; 92(4):691-696. PubMed ID: 35143093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.